Home » Beiträge » 9744

View Beitrag #9744

ID	9744
Ident	Teaser Low-Dose-Ass-Therapie / Medac (23.10./31.10.)
Titel	Low-Dose-ASS-Therapie in Kombination mit MTX in Rheumadosierung ist unbedenklich
Balkentitel	MEDAC INFORMIERT
Created	2023-08-07 14:36:34
Veraltet	0
typ_id	Universal 2023
sub_typ_id	Teaser
html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:5px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Low-Dose-ASS-Therapie in Kombination mit MTX in Rheumadosierung ist unbedenklich</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#005ca9"> </h3> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Die Unbedenklichkeit der Kombination Low-Dose-ASS + MTX in Rheumadosierung wird nun mit der evidenzbasierten, systematischen Literaturrecherche von Fiehn et al. 2023 bestätigt, die sich klar und deutlich zur Komedikation positioniert.<sup style="line-height:0">1</sup> Auch in einem systematischen Review der Cochrane Database wird dies bestätigt.<sup style="line-height:0">2</sup></p> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a target="_blank" href="https://www.deutschesapothekenportal.de/newsletter/2023q4/dap-dialog-77_medac-mtx-ass_interview-prof-dr-klaus-krueger.pdf" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Lesen Sie hier das Interview mit Prof. Dr. Klaus Krüger (PDF)</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">1 Fiehn et al. Z Rheumatol 2023; 82: 151–162. <a href="https://doi.org/10.1007/s00393-022-01308-z" target="_blank" style="text-decoration: none;font-size:11px;color:#005CA9">https://doi.org/10.1007/s00393-022-01308-z</a><br> 2 Colebatch N et al. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008872</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Typo3Html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:5px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Low-Dose-ASS-Therapie in Kombination mit MTX in Rheumadosierung ist unbedenklich</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#005ca9"> </h3> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Die Unbedenklichkeit der Kombination Low-Dose-ASS + MTX in Rheumadosierung wird nun mit der evidenzbasierten, systematischen Literaturrecherche von Fiehn et al. 2023 bestätigt, die sich klar und deutlich zur Komedikation positioniert.<sup style="line-height:0">1</sup> Auch in einem systematischen Review der Cochrane Database wird dies bestätigt.<sup style="line-height:0">2</sup></p> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a target="_blank" href="https://www.deutschesapothekenportal.de/newsletter/2023q4/dap-dialog-77_medac-mtx-ass_interview-prof-dr-klaus-krueger.pdf" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Lesen Sie hier das Interview mit Prof. Dr. Klaus Krüger (PDF)</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">1 Fiehn et al. Z Rheumatol 2023; 82: 151–162. <a href="https://doi.org/10.1007/s00393-022-01308-z" target="_blank" style="text-decoration: none;font-size:11px;color:#005CA9">https://doi.org/10.1007/s00393-022-01308-z</a><br> 2 Colebatch N et al. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008872</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

Newsletter 2023

2023-10-23 2023-10-31

Beitrag per e-mail verschicken

Auswertungsvorlage anzeigen

Statistik anzeigen